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Summary
Purpose: To evaluate the role of intravenous methyl prednisolone in patients with
solitary cysticercus granuloma with new-onset seizures.
Methods: In this open-label, randomized, prospective, follow-up study, 52 patients
with new-onset seizures and a single enhancing CT lesion of cysticercus were
randomly divided in two groups to receive either intravenous methyl prednisolone
for 5 days along with antiepileptic drug (n = 25) or antiepileptic drug monotherapy
(n = 27) alone. The patients were followed up for at least for 9 months. Repeat CT
scans were performed after 2 months.
Results: After 2 months, lesion disappeared in 60% patients of intravenous methyl
prednisolone group and 18.5% patients receiving only antiepileptic drug ( p = 0.001).
As far as seizure recurrence was concerned, a lower number (16% versus 33%) of
intravenous methyl prednisolone treated patient had recurrence, the difference was
insignificant.
Conclusion: Intravenous methyl prednisolone therapy helps in early resolution of
solitary cysticercus granuloma.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Solitary cysticercus granuloma is a common imaging
finding in Indian patients with focal and generalized* Corresponding author. Tel.: +91 522 3296978;
fax: +91 522 2257090.
E-mail address: garg50@yahoo.com (R.K. Garg).
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doi:10.1016/j.seizure.2006.03.003seizures.1—4 These lesions are reported to be the
cause of seizures in up to 50% of Indian patients
presenting with partial seizures.5,6 Many authors in
India have described spontaneous resolution of soli-
tary cysticercus granuloma.6—8 The time of sponta-
neous resolution, however, is variable. The reported
period of disappearance of lesion in these studies
varied from as low as 6 weeks to as long as 73. Published by Elsevier Ltd. All rights reserved.
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persist for a longer duration and cause calcifica-
tion7,8 and perilesional gliosis10, which are impor-
tant risk factors of seizure recurrence. So, an
effective intervention is desirable which may help
in early and complete resolution of the granuloma. A
recent report from our center demonstrates a ben-
eficial effect of short-term prednisolone in resolu-
tion of solitary cysticercus granuloma.11 However,
the therapeutic usage of oral prednisolone is asso-
ciated with potential side effects. The present study
was planned to assess the effect of potentially less
toxic intravenous methyl prednisolone on resolution
of solitary cysticercus granuloma.Figure 1 A contrast enhanced computed tomography
scan showing a solitary cysticercus granuloma with mild
perilesional oedema.Materials and methods
This prospective, randomized and open-label study
was conducted between February 2003 and January
2004 in department of Neurology of King George
Medical University, Lucknow, India. The institu-
tional ethics committee duly approved the study.
A total of 52 consecutive patients of new-onset
seizures who had a solitary contrast enhancing CT
lesion in brain parenchyma were included in this
study. All patients belonged to the North Indian
province of Uttar Pradesh, which is highly endemic
for infection with Taenia solium and cysticercosis.
Clinical and CT criteria given by Rajshekhar and
Chandy for solitary cysticercus granuloma were
used for inclusion of the patients. These criteria
were new-onset seizure (<14 days), no evidence of
increased intracranial pressure, no evidence of
neurological deficits, no evidence of other systemic
illness; CT scan showing a single enhancing CT
lesion of less than 20 mm in maximal dimensions12
(Fig. 1). The exclusion criteria were presence of
raised intracranial pressure, focal neurological
deficits (other than Todd’s palsy), intake of antic-
ysticercal treatment in recent past and history of
peptic ulcer disease. None of the patients needed
to be excluded on the basis of these exclusion
criteria.
After informed consent from the patients or
from legal guardians (in case of minor), patients
were subjected to a detailed systemic and neuro-
logical examination. All included patients were
subjected to a battery of investigations that
included complete blood count, plasma glucose,
creatinine, electrolytes and erythrocytes sedi-
mentation rate. The chest was radiographed for
possible pulmonary tuberculosis. All patients were
subjected to serum enzyme-linked immunosorbent
assay (ELISA) for human immunodeficiency virus.
Enzyme-linked immunoelectrotransfer blot assay(EITB) and Enzyme-linked immunosorbent assay
for Taenia solium were not done due to low sen-
sitivity in case of solitary cysticercus granu-
loma.13,14
All patients were randomly divided into two
groups: 25 patients in addition to antiepileptic drugs
received 5 days course of intravenous methyl pre-
dnisolone in dose of 1.0 g/1.72 m2/day (methyl pre-
dnisolone group) and the remaining 27 patients
received only antiepileptic drug (control group).
The randomization was done after inclusion with
the help of random number table. All patients were
put on single antiepileptic drug therapy (phenytoin
or carbamazepine). Initial drug dose was based on
body weights. In situations of seizure recurrence or
antiepileptic drug toxicity, appropriate dosage
adjustments or drug replacements were made.
Therapeutic drug monitoring of antiepileptic drug
was not performed. None of the patients of either
group was treated with anticysticercal drugs. Oral
corticosteroids were not given after intravenous
methyl prednisolone therapy.
Patients were followed up at monthly interval at
least for 9 months. Followed up CT scan were per-
formed in all patients of both groups after 2 months.
In the follow-up CT scan, 2 mm cuts of the regions
were taken. The lesions were considered ‘‘disap-
peared’’ when follow-up CT scan did not show any
lesion.
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Table 2 Follow-up CT scan after 2 months
Methyl
prednisolone
(n = 25)
Control
(n = 27)
Normal CT brain 15 (60%) 5 (18.5%)The analysis was done using chi-square test for
categorical observations and Students ’t’-test to
compare continuous observations such as age,
onset, number of seizures, and duration of illness
between two groups.(lesion disappeared) *
Abnormal CT (lesion
unresolved or
partially resolved)
10(40%) 22 (81.5%)
* x2 = 10.24; p = 0.001.Results
No significant difference was seen in any of the
epidemiological parameters between the intrave-
nous methyl prednisolone group (25 patients) and
the group that received only antiepileptic drug (27
patients). Approximately 80% of the included
patients were younger than 20 years. Simple partial
seizure with or without secondary generalizationTable 1 Clinical and radiologic characteristics of
patients of both groups
Methyl
prednisolone
(n = 25)
Control
(n = 27)
Age (years) (mean) 15.6  9 16  8
Sex
Male 17 (68%) 19 (70%)
Female 8 (32%) 8 (30%)
Duration (days) (mean) 8  2 8  2
Seizure type
Simple partial seizure 12 (48%) 10 (37%)
Partial seizure
with secondary
generalization
11 (44%) 14 (52%)
Generalized seizure 2 (8%) 3 (11%)
Number of seizure
Mean 2.5 2.4
Single seizure 10 (40%) 9 (33%)
Multiple seizure 15 (60%) 18 (67%)
Type of lesion
Colloidal
(ring enhancing)
22 (88%) 23 (85%)
Granular
(disc enhancing)
3 (12%) 4 (15%)
Size of lesion
<10 mm 10 (40%) 14 (52%)
10—15 mm 9 (36%) 9 (33%)
16—20 mm 6 (24%) 4 (15%)
Site
Frontal 9 (36%) 15 (56%)
Parietal 12 (48%) 9 (33%)
Occipital 2 (8%) 2 (7%)
Temporal 2 (8%) 1 (4%)
Oedema
Mild 16 (64%) 18 (67%)
Moderate 9 (36%) 9 (33%)was the most common type of seizure. Approxi-
mately 60% of patients in each group had more than
one seizure. Mean number of seizure at presentation
was 2.5 in each group. All included patients had a
seizure disorder of 14 days. The mean duration of
symptoms was about 8 days. Majority of lesions were
located either in frontal or parietal lobes. All
patients showed perilesional oedema. More than
two third of the enrolled patients had mild perile-
sional oedema (confined to same cerebral lobe),
whereas in the remaining one third perilesional
oedema was moderate (affecting the adjacent cer-
ebral lobe as well) (Table 1).
Our data suggested that treatment with intrave-
nous methyl prednisolone was associated with sig-
nificantly better response as far as complete
disappearance of solitary cysticercus granuloma
was concerned. After 2 months, lesion disappeared
in 15 out of 25 (60%) in intravenous methyl predni-
solone group and only 5 out of 27 (18.5%) in patients
of control group. This difference was statistically
significant (p = 0.001) (Table 2). As far as seizure
recurrence was concerned, 16% of intravenous
methyl prednisolone treated patient and 33% of
patients receiving only antiepileptic drugs had
recurrence ( p = 0.20) (Table 3). Recurrence of sei-
zure was associated with persistence of lesion
(either same or reduced in size) in 78% of intrave-
nous methyl prednisolone treated group and 75% in
control group (Table 4).
Eight percent of patients of intravenous methyl
prednisolone treated group developed mild pain in
abdomen, which responded to antacids. One patient
in control group developed rashes in the form of
erythema multiforme. In this patient carbamaze-
pine was changed to phenytoin.Table 3 Clinical outcome at 9 months
Methyl
prednisolone
(n = 25)
Control
(n = 27)
Recurrence of seizure 4 (16%) 9 (33%)
No recurrence 21 (84%) 18 (67%)
p = 0.20 (insignificant): Fisher exact test.
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Table 4 Follow-up computed tomography scan find-
ings in patients with seizure recurrence
Methyl
prednisolone
(n = 4)
Control
(n = 9)
Normal CT (lesion
disappeared)
1 (25%) 2 (22%)
Abnormal CT
(lesion unresolved
or partially resolved)
3 (75%) 7 (75%)Discussion
Seizures, in patients with solitary cysticercus gran-
uloma, are the result of the host inflammatory
response, even in patients who only have calcifica-
tions with no viable cysticerci. There is no general
consensus when or how to use corticosteroids to
suppress natural or treatment-induced inflamma-
tion around cysticercus granuloma. Corticosteroids
in patients with neurocysticercosis are frequently
empirically used along with anticysticercal drugs.
However, the role of corticosteroids in the manage-
ment of solitary cysticercus granuloma has scantly
been evaluated. In this study we have evaluated
intravenous methyl prednisolone in patients with
solitary cysticercus granuloma. Our data suggested
that treatment with intravenous methyl predniso-
lone lead to rapid resolution of lesion in signifi-
cantly higher number of patients. Intravenous
methyl prednisolone did not seem to affect possi-
ble seizure recurrence. Several histologic and
immunohistochemical studies have suggested that
solitary cysticercus granuloma consists of a dying
parasite larva, which is surrounded by a mature
granuloma with associated fibrosis, angiogenesis,
and an inflammatory infiltrate. The most abundant
cell types were plasma cells, B and T lymphocytes,
macrophages, and mast cells. Evidence exists of
the presence of secretion of several inflammatory
and antiinflammatory cytokines. It is believed that
the immunologic process elicited by the release of
dying parasite antigens is responsible for clinical
manifestations of neurocysticercosis.15,16 Possibly
antiinflammatory and immunosuppressive proper-
ties of intravenous methyl prednisolone on the
ongoing inflammatory process in brain parenchyma
and cyst wall was also expected to result in early
disappearance of granulomatous lesions. In a study
by Mall et al. short-term prednisolone therapy
was shown to help in rapid resolution of solitary
cysticercus granuloma in patients with new-onset
seizures. In this study resolution of lesions
was associated with improved seizure-related
prognosis.11Our observations are significant in view of sugges-
tion that the patients with solitary cysticercus gran-
uloma do not require conventional prolonged
antiepileptic therapy of 2—3 years once lesion has
disappeared. Murthy and Reddy in a retrospective
study of 102 patients of solitary cysticercus granu-
loma have shown that solitary cysticercus granu-
loma is a benign form of epilepsy and seizure recur
as long as the lesion persists. They recommended
that antiepileptic drug could safely be withdrawn
once the follow-up CTscan shows resolution of these
lesions.9 In our study treatment with intravenous
methyl prednisolone helped in complete resolution
of cysticercus granuloma. Many authors have shown
that recurrence of seizure is more common with
persistence of lesion. Pradhan et al. have shown that
recurrence of seizure may be due to perilesional
gliosis.10 In another study, Carpio and Hauser in a
randomized clinical trial of treatment of patients
with active neurocysticercosis observed that treat-
ment with oral prednisolone alone, praziquantel
with prednisolone, or albendazole with predniso-
lone, that at 6months and at 1 year after treatment,
there were no differences in the three treatment
groups in terms of the proportion of patients who
were free of cysts or the relative reduction of
number of cysts. At 2 years, there was no difference
in the proportion of patients free of seizures during
the entire follow-up period. Early and late sequelae,
like such as epilepsy or hydrocephalus, occurred in a
higher proportion of patients treated with prazi-
quantel and albendazole, compared with those
receiving only prednisolone.17 In another study by
Kalra et al. authors observed that treatment with
albendazole and dexamethasone expedited the
complete or partial resolution of lesions and also
reduced the risk of subsequent seizure recurrence
among children.18
We could not observe expected favorable
response of corticosteroids on seizure prognosis.
In a recent study similar observation about unfa-
vorable seizure prognosis was also reported with
oral prednisolone. Singhi et al. conducted a rando-
mized prospective trial to evaluate the efficacy of
corticosteroids, albendazole, and corticosteroids
with albendazole in children with solitary cysticer-
cus granuloma. All 110 children were randomly
assigned to receive corticosteroids, albendazole,
or both corticosteroids and albendazole for 28
days. There was no significant difference in resolu-
tion of cysticercus granuloma in the three therapy
group. Among 23 patients who had seizure recur-
rence 36.8% were in corticosteroids group, 13.5% in
albendazole group, and 11.4% in which received
both. Seizure recurrence after antiepileptic drugs
withdrawal was seen in seven children (three in
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group and in group which received both.19 Possibly,
the short-term administration of corticosteroids
might have altered the immune equilibrium in
patients with cysticercus granuloma leading to rapid
but incomplete granuloma resolution. So, possibility
of seizure recurrence remained unaffected.We think
that there is a need for large controlled trial to
further clarify this important finding.
The role of albendazole therapy in patients with
neurocysticercosis has been the subject of consid-
erable debate and controversy. Controlled clinical
trials have demonstrated that antiparasitic drugs in
patients with viable neurocysticercosis lesions can
decrease the number of generalized seizures,
although the benefit is small and confined to a
subgroup of patients.20 Although some clinicians
argue in favor of the routine use of anticysticidal
drugs in patients with viable cysticercal lesions and
even in those with solitary cysticercus granuloma,
others believe that albendazole does not alter sei-
zure outcome in patients with neurocysticercosis.
Several authors believe that concurrent administra-
tion of dexamethasone in standard doses is usually
required during the first several days of antiparasitic
therapy to minimize the inflammation and cerebral
edema associated with death of the parasites.20—22
In our study, we selected only patients with soli-
tary cysticercus granuloma. Our findings would not
apply to the patients with multiple viable lesions and
patients with extraparenchymal neurocysticercosis.
Antiinflammatory properties of intravenous
methyl prednisolone therapy help in early resolution
of solitary cysticercus granuloma.References
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